Presentationer & publikationer

"Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the Phase 3 NefIgArd trial"

World Congress of Nephrology april 2024

Nefecon effect on quality of life in patients with IgAN: SF-36 results from the Phase 3 NefIgArd trial

World Congress of Nephrology april 2024

eGFR decline in patients with IgAN treated with Nefecon or placebo: Results from the 2-year NefIgArd Phase 3 trial

World Congress of Nephrology april 2024

Nefecon treatment provides kidney benefits for patients with IgAN that extend to those with low levels of UPCR: A sub-analysis of the phase III NefIgArd trial

World Congress of Nephrology april 2024

Analysis of the NefIgArd Part A study confirms Nefecon modulated proteins involved in the intestinal immune network for IgA production

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

Analysis of the NefIgArd Part A study population confirms Nefecon reduces levels of dietary antigen-specific IgA in patients with IgA nephropathy

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

Modeling based on NefIgArd 2-year eGFR total slope predicts long-term clinical benefit of Nefecon in a real-world IgAN population

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

TRF-budesonide (Nefecon) reduces serum biomarkers of lymphocyte activation in IgA nephropathy, which correlate with changes in serum BAFF levels

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

eGFR decline in patients with IgAN treated with Nefecon or placebo: Results from the 2-year NefIgArd Phase 3 trial

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

The NOX inhibitor setanaxib combined with ramipril reduces glomerular function decline and fibrosis in a mouse model of Alport syndrome

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

Long-term renal benefit with Nefecon in Chinese patients with primary immunoglobulin A nephropathy 2-year NefIgArd trial results

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

Design and Rationale for PERFORM Patient Registry™: An Observational Cohort of Patients Utilizing TARPEYO® for Immunoglobulin A Nephropathy (IgAN) in the United States

the American Society of Nephrology (ASN) Kidney Week 2023 november 2023

Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the Phase 3 NefIgArd trial

17th International Symposium on IgA Nephropathy september 2023

Hematuria reduction in patients with IgAN following Nefecon treatment:A secondary analysis of the full 2-year NeflgArd Phase 3 trial results

17th International Symposium on IgA Nephropathy september 2023

Analysis of the NefIgArd Part A study population confirms Nefecon suppresses circulating levels of BAFF, APRIL, and soluble BCMA in IgAnephropathy

17th International Symposium on IgA Nephropathy september 2023

Comparison of the dissolution profile of Nefecon with three other commercially available oral formulations of budesonide: Implications for interchangeability

17th International Symposium on IgA Nephropathy september 2023

Durable proteinuria reduction over 2 years with Nefecon treatment: A secondary analysis of the full NefIgArd Phase 3 trial results

17th International Symposium on IgA Nephropathy september 2023

Long-term renal benefit over 2 years with Nefecon verified: The NefIgArd Phase 3 full trial results

17th International Symposium on IgA Nephropathy september 2023

Analysis of the NefIgArd Part A study population confirms Nefecon suppresses circulating levels of IgA-containing immune complexes in IgA nephropathy

17th International Symposium on IgA Nephropathy september 2023

Analysis of the NefIgArd Part A study population confirms that Nefecon modulates circulating levels of the chemokines CXCL5, CCL11, and CCL13 in IgA nephropathy

17th International Symposium on IgA Nephropathy september 2023

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

The Lancet augusti 2023

Durable proteinuria reduction over 2 years with Nefecon treatment: A secondary analysis of the full NefIgArd Phase 3 trial results

60^th European Renal Association Congress juni 2023

Hematuria reduction in patients with IgAN following Nefecon treatment: A secondary analysis of the full 20year NefIgArd Phase 3 trial results

60^th European Renal Association Congress juni 2023

Nefecon treatment likely modulates downstream pathways of kidney inflammation and fibrosis in IgA nephropathy

60^th European Renal Association Congress juni 2023

Long-term renal benefit over 2 years with Nefecon verified: The NefigArd Phase 3 full trial results

60^th European Renal Association Congress juni 2023

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States

ClinicoEconomics and Outcomes Research mars 2023

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Kidney International oktober 2022